We are a science-driven global biotech company

Transforming Potential into Reality

Find out more

Pipeline

Latest News

Press Releases

2024.06.06

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

ROCKVILLE, MD, June 6, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, […]

2024.06.05

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. Collaboration builds on promising safety and efficacy data from the givastomig monotherapy study reported at the European Society of Medical Oncology Congress 2023. ROCKVILLE, […]

2024.05.23

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

– Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors – Phase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses – Data will be presented at the 2024 Annual […]

Our Purposeful Journey to Bring Innovative Medicines to People We Serve

Founded

I-Mab was established in June 2016

Series A Financing

I-Mab completed Series A financing, raising $58 million

Merger & Series B Financing

Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing

Series C Financing

I-Mab successfully raised $227 million in Series C Financing

Nasdaq Listing

I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company

AbbVie Global Partnership

I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab

Private Placement with Hillhouse Capital-Led Consortium

I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium

Global Footprint

I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou

Jumpcan Partnership

I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China

U.S.-Based Biotech

I-Mab signed agreement to divest its assets and business operations in China, bringing a greater focus on the U.S. and ex-China markets